{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-159062","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.541511+00:00","generated_at":"2026-05-15T05:47:06.791920+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Corbus Pharma amends employment agreements: CEO salary $673,625, CFO salary $501,273","bullets":["New employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026.","CEO Cohen: base salary $673,625, bonus target up to 60%, term through April 15, 2028.","CFO Moran: base salary $501,273, bonus target up to 40%, term through April 15, 2028.","CEO severance: 12 months' base salary, COBRA; change-in-control: 24 months, 2x bonus, full vesting.","CFO severance: 12 months' base salary, COBRA; change-in-control: 18 months, 1x bonus, full vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-159062","json":"https://secwatch.observer/filing/0001193125-26-159062.json","markdown":"https://secwatch.observer/filing/0001193125-26-159062.md","text":"https://secwatch.observer/filing/0001193125-26-159062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526159062/0001193125-26-159062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526159062/crbp-20260415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:47:06.791920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}